Please enable JavaScript to continue using this application.

Compare $GLUE vs $ODTX | Chartloom

Compare

$GLUE vs $ODTX

Monte Rosa Therapeutics Inc · Odyssey Therapeutics Inc

GLUE

Monte Rosa Therapeutics Inc

ODTX

Odyssey Therapeutics Inc

Compare $GLUE vs $ODTX

Comparing Monte Rosa Therapeutics Inc and Odyssey Therapeutics Inc

GLUEMonte Rosa Therapeutics Inc

ODTXOdyssey Therapeutics Inc

GLUEMonte Rosa Therapeutics Inc

Market cap

$870M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

21.85x

Rev growth (TTM)

-83.9%

YTD performance

-32.7%

52W performance

33.6%

FCF yield

-3.7%

ODTXOdyssey Therapeutics Inc

Market cap

$913M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-19.0%

YTD performance

15.7%

52W performance

15.7%

FCF yield

-4.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

GLUE

ODTX

Detailed metrics comparison

GLUE

Monte Rosa Therapeutics Inc

ODTX

Odyssey Therapeutics Inc

Market Cap

GLUE$870M

ODTX$913M

Enterprise Value

GLUE$780M

ODTX$831M

Price

GLUE$10.30

ODTX$19.00

P/E Ratio

GLUEN/A

ODTXN/A

P/S Ratio

GLUE30.29x

ODTX306.64x

EV/Sales

GLUE27.15x

ODTX279.08x

EV/EBITDA

GLUE47.84x

ODTX0.00x

P/B Ratio

GLUE1.84x

ODTX2.36x

P/FCF Ratio

GLUEN/A

ODTXN/A

EV/FCF

GLUE-24.32x

ODTX-21.89x

PEG Ratio

GLUEN/A

ODTXN/A

Forward P/E (NTM)

GLUEN/A

ODTXN/A

Forward P/S (NTM)

GLUE21.85x

ODTXN/A

Revenue (TTM)

GLUE$29M

ODTX$3M

Revenue Growth (YoY)

GLUE-83.9%

ODTX-19.0%

Forward Rev Growth

GLUE-58.1%

ODTX410.3%

Gross Margin (TTM)

GLUE0.0%

ODTX0.0%

Operating Margin (TTM)

GLUE0.0%

ODTX0.0%

EBITDA Margin (TTM)

GLUE-604.8%

ODTX-3193.4%

Net Margin (TTM)

GLUE-560.9%

ODTX-8054.3%

FCF Margin (TTM)

GLUE-111.7%

ODTX-1275.0%

Net Income (TTM)

GLUE$-161M

ODTX$-240M

FCF (TTM)

GLUE$-32M

ODTX$-38M

EPS (TTM)

GLUE-$1.59

ODTX-$7.92

ROE (TTM)

GLUE-4331.0%

ODTX-3030.0%

ROA (TTM)

GLUE-2759.0%

ODTX-2554.0%

ROIC (TTM)

GLUE-4331.0%

ODTX-3030.0%

Cash

GLUE$90M

ODTX$82M

Debt

GLUE$0

ODTX$0

Net Cash/Debt

GLUE$90M

ODTX$82M

Current Ratio (TTM)

GLUE10.58x

ODTX11.36x

Quick Ratio (TTM)

GLUE10.49x

ODTX10.98x

Debt/Equity (TTM)

GLUE0.00x

ODTX0.00x

Debt/Assets (TTM)

GLUE0.0%

ODTX0.0%

Interest Coverage (TTM)

GLUEN/A

ODTXN/A

Net Debt/EBITDA (TTM)

GLUE0.00x

ODTX0.00x

Beta

GLUE1.34

ODTX-0.23

52W Performance

GLUE33.6%

ODTX15.7%

YTD Performance

GLUE-32.7%

ODTX15.7%

% from 52W High

GLUE-60.0%

ODTX-34.6%

% from 52W Low

GLUE34.7%

ODTX25.8%

Asset Turnover (TTM)

GLUE0.05x

ODTX0.00x

FCF Yield (TTM)

GLUE-3.7%

ODTX-4.2%

Earnings Yield (TTM)

GLUE-18.5%

ODTX-26.3%

Dividend Yield (TTM)

GLUEN/A

ODTXN/A

Rule of 40

GLUE-195.5

ODTX-1,294.1

EV/GP/RG

GLUEN/A

ODTXN/A

Ticker research

View GLUE research View ODTX research

Metric	GLUE Monte Rosa Therapeutics Inc	ODTX Odyssey Therapeutics Inc
Market & Valuation
Market Cap	$870M	$913M
Enterprise Value	$780M	$831M
Price	$10.30	$19.00
P/E Ratio	N/A	N/A
P/S Ratio	30.29x	306.64x
EV/Sales	27.15x	279.08x
EV/EBITDA	47.84x	0.00x
P/B Ratio	1.84x	2.36x
P/FCF Ratio	N/A	N/A
EV/FCF	-24.32x	-21.89x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	21.85x	N/A
Revenue & Growth
Revenue (TTM)	$29M	$3M
Revenue Growth (YoY)	-83.9%	-19.0%
Forward Rev Growth	-58.1%	410.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-604.8%	-3193.4%
Net Margin (TTM)	-560.9%	-8054.3%
FCF Margin (TTM)	-111.7%	-1275.0%
Net Income (TTM)	$-161M	$-240M
FCF (TTM)	$-32M	$-38M
EPS (TTM)	-$1.59	-$7.92
ROE (TTM)	-4331.0%	-3030.0%
ROA (TTM)	-2759.0%	-2554.0%
ROIC (TTM)	-4331.0%	-3030.0%
Financial Health
Cash	$90M	$82M
Debt	$0	$0
Net Cash/Debt	$90M	$82M
Current Ratio (TTM)	10.58x	11.36x
Quick Ratio (TTM)	10.49x	10.98x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.34	-0.23
52W Performance	33.6%	15.7%
YTD Performance	-32.7%	15.7%
% from 52W High	-60.0%	-34.6%
% from 52W Low	34.7%	25.8%
Efficiency & Yields
Asset Turnover (TTM)	0.05x	0.00x
FCF Yield (TTM)	-3.7%	-4.2%
Earnings Yield (TTM)	-18.5%	-26.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-195.5	-1,294.1
EV/GP/RG	N/A	N/A
Ticker research	View GLUE research	View ODTX research

Valuation

P/S Ratio

GLUE

30.29x

ODTX

306.64x

EV/FCF

GLUE

-24.32x

ODTX

-21.89x

Growth & revenue

Revenue Growth TTM

ODTX

-19.0%

GLUE

-83.9%

Forward Revenue Growth

ODTX

410.3%

GLUE

-58.1%

Profitability & performance

Gross Margin

GLUE

0.0%

ODTX

0.0%

ROE

ODTX

-3030.0%

GLUE

-4331.0%

FCF Yield %

GLUE

-3.7%

ODTX

-4.2%

52-Week Performance

GLUE

33.6%

ODTX

15.7%

Detailed metrics comparison

GLUE

Monte Rosa Therapeutics Inc

ODTX

Odyssey Therapeutics Inc

Market Cap

GLUE$870M

ODTX$913M

Enterprise Value

GLUE$780M

ODTX$831M

Price

GLUE$10.30

ODTX$19.00

P/E Ratio

GLUEN/A

ODTXN/A

P/S Ratio

GLUE30.29x

ODTX306.64x

EV/Sales

GLUE27.15x

ODTX279.08x

EV/EBITDA

GLUE47.84x

ODTX0.00x

P/B Ratio

GLUE1.84x

ODTX2.36x

P/FCF Ratio

GLUEN/A

ODTXN/A

EV/FCF

GLUE-24.32x

ODTX-21.89x

PEG Ratio

GLUEN/A

ODTXN/A

Forward P/E (NTM)

GLUEN/A

ODTXN/A

Forward P/S (NTM)

GLUE21.85x

ODTXN/A

Revenue (TTM)

GLUE$29M

ODTX$3M

Revenue Growth (YoY)

GLUE-83.9%

ODTX-19.0%

Forward Rev Growth

GLUE-58.1%

ODTX410.3%

Gross Margin (TTM)

GLUE0.0%

ODTX0.0%

Operating Margin (TTM)

GLUE0.0%

ODTX0.0%

EBITDA Margin (TTM)

GLUE-604.8%

ODTX-3193.4%

Net Margin (TTM)

GLUE-560.9%

ODTX-8054.3%

FCF Margin (TTM)

GLUE-111.7%

ODTX-1275.0%

Net Income (TTM)

GLUE$-161M

ODTX$-240M

FCF (TTM)

GLUE$-32M

ODTX$-38M

EPS (TTM)

GLUE-$1.59

ODTX-$7.92

ROE (TTM)

GLUE-4331.0%

ODTX-3030.0%

ROA (TTM)

GLUE-2759.0%

ODTX-2554.0%

ROIC (TTM)

GLUE-4331.0%

ODTX-3030.0%

Cash

GLUE$90M

ODTX$82M

Debt

GLUE$0

ODTX$0

Net Cash/Debt

GLUE$90M

ODTX$82M

Current Ratio (TTM)

GLUE10.58x

ODTX11.36x

Quick Ratio (TTM)

GLUE10.49x

ODTX10.98x

Debt/Equity (TTM)

GLUE0.00x

ODTX0.00x

Debt/Assets (TTM)

GLUE0.0%

ODTX0.0%

Interest Coverage (TTM)

GLUEN/A

ODTXN/A

Net Debt/EBITDA (TTM)

GLUE0.00x

ODTX0.00x

Beta

GLUE1.34

ODTX-0.23

52W Performance

GLUE33.6%

ODTX15.7%

YTD Performance

GLUE-32.7%

ODTX15.7%

% from 52W High

GLUE-60.0%

ODTX-34.6%

% from 52W Low

GLUE34.7%

ODTX25.8%

Asset Turnover (TTM)

GLUE0.05x

ODTX0.00x

FCF Yield (TTM)

GLUE-3.7%

ODTX-4.2%

Earnings Yield (TTM)

GLUE-18.5%

ODTX-26.3%

Dividend Yield (TTM)

GLUEN/A

ODTXN/A

Rule of 40

GLUE-195.5

ODTX-1,294.1

EV/GP/RG

GLUEN/A

ODTXN/A

Ticker research

View GLUE research View ODTX research

Metric	GLUE Monte Rosa Therapeutics Inc	ODTX Odyssey Therapeutics Inc
Market & Valuation
Market Cap	$870M	$913M
Enterprise Value	$780M	$831M
Price	$10.30	$19.00
P/E Ratio	N/A	N/A
P/S Ratio	30.29x	306.64x
EV/Sales	27.15x	279.08x
EV/EBITDA	47.84x	0.00x
P/B Ratio	1.84x	2.36x
P/FCF Ratio	N/A	N/A
EV/FCF	-24.32x	-21.89x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	21.85x	N/A
Revenue & Growth
Revenue (TTM)	$29M	$3M
Revenue Growth (YoY)	-83.9%	-19.0%
Forward Rev Growth	-58.1%	410.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-604.8%	-3193.4%
Net Margin (TTM)	-560.9%	-8054.3%
FCF Margin (TTM)	-111.7%	-1275.0%
Net Income (TTM)	$-161M	$-240M
FCF (TTM)	$-32M	$-38M
EPS (TTM)	-$1.59	-$7.92
ROE (TTM)	-4331.0%	-3030.0%
ROA (TTM)	-2759.0%	-2554.0%
ROIC (TTM)	-4331.0%	-3030.0%
Financial Health
Cash	$90M	$82M
Debt	$0	$0
Net Cash/Debt	$90M	$82M
Current Ratio (TTM)	10.58x	11.36x
Quick Ratio (TTM)	10.49x	10.98x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.34	-0.23
52W Performance	33.6%	15.7%
YTD Performance	-32.7%	15.7%
% from 52W High	-60.0%	-34.6%
% from 52W Low	34.7%	25.8%
Efficiency & Yields
Asset Turnover (TTM)	0.05x	0.00x
FCF Yield (TTM)	-3.7%	-4.2%
Earnings Yield (TTM)	-18.5%	-26.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-195.5	-1,294.1
EV/GP/RG	N/A	N/A
Ticker research	View GLUE research	View ODTX research